Skip Navigation


CIT can broadcast your seminar, conference or meeting live to a world-wide audience over the Internet as a real-time streaming video. The event can be recorded and made available for viewers to watch at their convenience as an on-demand video or a downloadable podcast. CIT can also broadcast NIH-only or HHS-only content.

Defining the Spectrum of Resistance to be Targeted Anti-Cancer Therapeutics

Loading video...

387 Views  
   
Air date: Wednesday, September 5, 2012, 3:00:00 PM
Time displayed is Eastern Time, Washington DC Local
Views: Total views: 387, (147 Live, 240 On-demand)
Category: WALS - Wednesday Afternoon Lectures
Runtime: 01:03:16
Description: Dr. Levi Garraway has made seminal research contributions in cancer genomics, drug resistance, and genomics-driven (or “personalized”) cancer medicine. He published the first genome sequencing studies of aggressive primary prostate cancer, and has led other major sequencing initiatives in prostate cancer, melanoma and head/neck cancers. This work identified multiple new cancer genes and uncovered mechanisms by which complex rearrangements arise. At the Broad Institute, he leads the Cancer Cell Line Encyclopedia, a collaboration with Novartis that involves a genomic and pharmacological study of ~1000 human cancer cell lines to characterize sensitivity and resistance to anticancer agents.

Dr. Garraway is perhaps best known for his contributions to precision cancer medicine. He described the first high-throughput adaptation of a genomic technology to profile human tumors for hundreds of “actionable” cancer gene mutations. This provided a basis for tumor mutation profiling as a means to stratify cancer patients for clinical trial enrollment and, in the future, optimal therapeutic choices. He also demonstrated the promise of massive parallel sequencing as a clinical tumor genomic profiling approach. This research has inspired personalized medicine initiatives at many cancer centers worldwide.

Dr. Garraway has been the recipient of several awards and honors, including the Minority Scholar Award from the American Association of Cancer Research, the Partners in Excellence Award, and the Burroughs-Wellcome Fund Career Award in the Biomedical Sciences. In the fall of 2007, he was awarded one of the first prestigious New Innovator Awards from the National Institutes of Health. In 2009, he was inducted into the American Society for Clinical Investigation.

Wednesday Afternoon Lecture Series

For more information go to http://wals.od.nih.gov/
Debug: Show Debug
NLM Title: Defining the spectrum of resistance to be targeted anti-cancer therapeutics [electronic resource] / Levi A. Garraway.
Series: NIH Wednesday afternoon lecture
Author: Garraway, Levi A.
National Institutes of Health (U.S.)
Publisher:
Other Title(s): NIH Wednesday afternoon lecture
Abstract: (CIT): Dr. Levi Garraway has made seminal research contributions in cancer genomics, drug resistance, and genomics-driven (or "personalized") cancer medicine. He published the first genome sequencing studies of aggressive primary prostate cancer, and has led other major sequencing initiatives in prostate cancer, melanoma and head/neck cancers. This work identified multiple new cancer genes and uncovered mechanisms by which complex rearrangements arise. At the Broad Institute, he leads the Cancer Cell Line Encyclopedia, a collaboration with Novartis that involves a genomic and pharmacological study of ~1000 human cancer cell lines to characterize sensitivity and resistance to anticancer agents. Dr. Garraway is perhaps best known for his contributions to precision cancer medicine. He described the first high-throughput adaptation of a genomic technology to profile human tumors for hundreds of "actionable" cancer gene mutations. This provided a basis for tumor mutation profiling as a means to stratify cancer patients for clinical trial enrollment and, in the future, optimal therapeutic choices. He also demonstrated the promise of massive parallel sequencing as a clinical tumor genomic profiling approach.
Subjects: Drug Resistance, Neoplasm
Molecular Targeted Therapy
Neoplasms--drug therapy
Publication Types: Lectures
Webcasts
Download: To download this event, select one of the available bitrates:
[256k]  [512k]    How to download a Videocast
Caption Text: Download Caption File
NLM Classification: QZ 267
NLM ID: 101595128
CIT Live ID: 11848
Permanent link: https://videocast.nih.gov/launch.asp?17545

 

Podcast information
Audio Podcasts   Video Podcasts
  Description Runtime     Description Runtime
      Watch the podcast Audio Podcast 01:04:09
      Watch the podcast Video Podcast (CC) 01:04:09